Quantcast

Latest Human Genome Sciences Stories

2008-08-27 09:00:23

ROCKVILLE, Md., Aug. 27 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced it has completed enrollment and initial dosing in BLISS-76, the second of two pivotal Phase 3 randomized clinical trials of LymphoStat-B(R) (belimumab) in patients with active systemic lupus erythematosus (SLE). Belimumab is being developed by HGS and GlaxoSmithKline (GSK) under a co-development and commercialization agreement entered into in August 2006. (Logo:...

2008-08-25 12:01:19

Human Genome Sciences has completed enrollment and initial dosing of patients in a randomized Phase II trial of HGS-ETR1 in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. The non-small cell lung cancer (NSCLC) trial is a randomized, multi-center, open-label Phase II study to evaluate the efficacy and safety of HGS-ETR1 in combination with carboplatin and paclitaxel as first-line therapy in the treatment of...

2008-08-22 09:00:16

ROCKVILLE, Md., Aug. 22 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced that it has completed the enrollment and initial dosing of patients in a randomized Phase 2 trial of HGS-ETR1 (mapatumumab) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) "There is an urgent medical need for effective treatment options for...

2008-07-30 18:00:55

ROCKVILLE, Md., July 30 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced financial results and key developments for the quarter ended June 30, 2008. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) "During the second quarter, we continued to make excellent progress in our Phase 3 trials of Albuferon(R) in chronic hepatitis C and LymphoStat-B(R) in systemic lupus erythematosus," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "Our...

2008-07-24 09:01:14

ROCKVILLE, Md., July 24 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced that David P. Southwell has been appointed to the HGS Board of Directors. He will also serve as a member of the Company's Audit Committee. Until recently, Mr. Southwell was at Sepracor, Inc., a research-based pharmaceutical company, where he served as Executive Vice President and Chief Financial Officer, and also had responsibility for Corporate Planning, Development and Licensing. (Logo:...

2006-08-09 08:00:00

BOSTON - Biotechnology company Human Genome Science Inc. said on Wednesday that it plans shortly to seek approval from U.S. regulators to run a late-stage clinical trial of its drug to treat systemic lupus erythematosus, a chronic, life-threatening disease. If the U.S. Food and Drug Administration approves Human Genome's proposal for the design of its Phase III clinical trial, the company could begin enrollment by the end of this year. This is the first time Human Genome Sciences has brought...

2005-10-03 00:32:40

WASHINGTON (Reuters) - Human Genome Sciences Inc. plans to announce a deal with the U.S. government on Monday to provide as many as 100,000 doses of an experimental anthrax drug, the Washington Post reported. The Rockville, Maryland-based company will sell the government a third of an ounce of the drug for $1.8 million, an amount sufficient for government testers to compare the product with competitors, the paper said. On Friday, U.S. officials awarded a similar contract to...

2004-11-30 09:00:10

ROCKVILLE, Md., Nov. 30 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. announced today that it has completed the enrollment and initial dosing of patients in a Phase 2 clinical trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL Receptor 1) in patients with advanced non- small cell lung cancer. The multi-center, open-label, single-arm Phase 2 clinical trial is designed to evaluate the efficacy, safety and tolerability of HGS-ETR1 in patients with relapsed or refractory...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related